Current and historical daily PE Ratio for Boston Scientific Corp (
FRA:BSX
) from 1992 to May 01 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Boston Scientific stock (FRA:BSX) PE ratio as of May 01 2024 is 60.39.
More Details
Boston Scientific Corp (FRA:BSX) PE Ratio (TTM) Chart
Boston Scientific Corp (FRA:BSX) PE Ratio (TTM) Historical Data
View and export this data going back to 1992. Start your Free Trial
Total 1229
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Boston Scientific PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-01 | 61.8 | 2024-02-26 | 62.1 |
| 2024-04-30 | 61.8 | 2024-02-23 | 62.5 |
| 2024-04-29 | 61.8 | 2024-02-22 | 61.8 |
| 2024-04-26 | 61.8 | 2024-02-21 | 62.2 |
| 2024-04-25 | 62.7 | 2024-02-20 | 61.9 |
| 2024-04-24 | 62.2 | 2024-02-19 | 61.3 |
| 2024-04-23 | 57.7 | 2024-02-16 | 62.1 |
| 2024-04-22 | 57.2 | 2024-02-15 | 61.8 |
| 2024-04-19 | 57.2 | 2024-02-14 | 61.4 |
| 2024-04-18 | 58.1 | 2024-02-13 | 61.0 |
| 2024-04-17 | 57.7 | 2024-02-12 | 60.5 |
| 2024-04-16 | 57.7 | 2024-02-09 | 60.9 |
| 2024-04-15 | 58.1 | 2024-02-08 | 60.6 |
| 2024-04-12 | 58.1 | 2024-02-07 | 61.4 |
| 2024-04-11 | 57.7 | 2024-02-06 | 60.2 |
| 2024-04-10 | 57.7 | 2024-02-05 | 60.4 |
| 2024-04-09 | 56.8 | 2024-02-02 | 60.2 |
| 2024-04-08 | 56.8 | 2024-02-01 | 59.1 |
| 2024-04-05 | 56.8 | 2024-01-31 | 59.3 |
| 2024-04-04 | 57.2 | 2024-01-30 | 56.8 |
| 2024-04-03 | 56.8 | 2024-01-29 | 56.7 |
| 2024-04-02 | 56.8 | 2024-01-26 | 56.3 |
| 2024-03-28 | 57.8 | 2024-01-25 | 55.7 |
| 2024-03-27 | 63.2 | 2024-01-24 | 55.8 |
| 2024-03-26 | 62.8 | 2024-01-23 | 56.2 |
| 2024-03-25 | 62.8 | 2024-01-22 | 56.4 |
| 2024-03-22 | 62.6 | 2024-01-19 | 55.8 |
| 2024-03-21 | 61.6 | 2024-01-18 | 56.4 |
| 2024-03-20 | 63.4 | 2024-01-17 | 56.4 |
| 2024-03-19 | 62.2 | 2024-01-16 | 55.6 |
| 2024-03-18 | 61.0 | 2024-01-12 | 55.1 |
| 2024-03-15 | 61.3 | 2024-01-11 | 54.8 |
| 2024-03-14 | 60.9 | 2024-01-10 | 54.4 |
| 2024-03-13 | 61.3 | 2024-01-09 | 54.1 |
| 2024-03-12 | 61.9 | 2024-01-08 | 53.3 |
| 2024-03-11 | 61.3 | 2024-01-05 | 53.4 |
| 2024-03-08 | 62.1 | 2024-01-04 | 53.1 |
| 2024-03-07 | 62.2 | 2024-01-03 | 53.4 |
| 2024-03-06 | 61.9 | 2024-01-02 | 52.5 |
| 2024-03-05 | 62.4 | 2023-12-29 | 51.8 |
| 2024-03-04 | 62.0 | 2023-12-28 | 50.6 |
| 2024-03-01 | 62.0 | 2023-12-27 | 66.0 |
| 2024-02-29 | 61.4 | 2023-12-22 | 65.6 |
| 2024-02-28 | 61.7 | 2023-12-21 | 65.9 |
| 2024-02-27 | 61.6 | 2023-12-20 | 66.2 |
Boston Scientific Corp (FRA:BSX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Boston Scientific Corp
NAICS : 339112
SIC : 3841
ISIN : US1011371077
Share Class Description:
FRA:BSX: Ordinary SharesCompare
Compare
Traded in other countries / regions
BSX.USABSX.MexicoBSX.Germany1BSX.ItalyBSXC.AustriaB1SX34.Brazil0HOY.UKBSX.Peru IPO Date
1992-05-18Description
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers